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Abstract
In humans, iron deficiency represents a relevant occurrence in heart failure (HF), with or 
without anaemia, and is associated with the worst outcome. Moreover, chronic kidney disease 
(CKD) is a well-known comorbidity of HF and is strongly associated with the risk of developing 
anaemia. The most common cause of HF in dogs is myxomatous mitral valve disease (MMVD). 
To the best of our knowledge, no studies have examined the iron status in dogs with HF, with and 
without CKD. The aim of this retrospective study was to evaluate the iron status in dogs affected 
by MMVD and how strong is the relation with HF. 
The retrospective study included 54 dogs with complete case records, echocardiography and 
laboratory analyses. Iron status was evaluated by measuring serum iron concentration (SIC), un-
saturated iron binding capacity (UIBC), total iron binding capacity (TIBC), and percentage of 
saturation (%SAT). 
The prevalence of dogs showing low serum iron concentration (SIC) was 18% in the whole 
population, 33% in symptomatic patients, 100% in dogs with acute decompensated HF. No signif-
icant differences in SIC, UIBC, TIBC and %SAT median values were found among dogs classi-
fied in different ACVIM (American College of Veterinary Internal Medicine) classes, between 
symptomatic and non-symptomatic patients, and among IRIS (International Renal Interest Soci-
ety) classes. Azotemic and non-azotemic patients presented a significant difference in SIC mean 
values (p=0.02). Generalised linear model (GLM) revealed that dogs with low SIC were at high-
er risk of being included in a higher ACVIM class (OR=6.383, p-value=0.014). 
Log-rank analysis showed shorter survival in dogs with low SIC (p=0.020), multivariate Cox 
analysis revealed that only HF symptoms can affect survival.
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lar-renal disorder
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Introduction
In human medicine, recent studies have highlighted 
the role of iron deficiency (ID) in heart failure (HF) 
patients. Dysregulation of iron metabolism was gener-
ally considered relevant only in association with anae-
mia, which have a prevalence of approximately 50% 
(Okonko et al. 2011, Arora et al. 2014). Nevertheless, 
recent studies have found that the prevalence of serum 
iron deficiency (SID) in HF can be higher than the 
prevalence of anaemia and varies from 37% to 61% 
(Wong et al. 2016). In these patients, ID can also be 
present in the absence of anaemia and is associated 
with the worst symptoms (Klip et al. 2013, Rangel et al. 
2014, Fitzsimmons et al. 2015). ID represents an in-
creased risk of mortality and morbidity itself (Klip et al. 
2013, Rangel et al. 2014, Fitzsimmons et al. 2015). 
Moreover, ID is responsible for exercise intolerance, 
reduction in quality of life, and can promote cardiac 
remodelling, as shown in murine animal models (Nayto 
et al. 2009, Wong et al. 2016). Myocites and cardio-
myocites are in fact cells with elevated energy demand, 
for which the maintenance of a correct iron metabolism 
is fundamental. Alterations in this metabolism can pro-
mote impairment in oxidative and cellular energy 
metabolism (Arora et al. 2014). 
The pathogenetic hypotheses proposed to explain 
ID in HF are insufficient dietary iron intake, poor gas-
trointestinal iron absorption due to intestinal mucosa 
oedema, hepcidin overexpression due to a chronic 
inflammatory state caused by HF, and the use of certain 
drugs such as anticoagulants or ACE inhibitors that can 
reduce erythropoietin production (Van der Meer et al. 
2004, Opasich et al. 2005, Kazory et al. 2009). 
ID can be defined as absolute or functional and 
both can be found in patients affected by heart diseases 
(Jankowska et al. 2013). 
In fact, impaired absorption from the gastrointesti-
nal (GI) tract, chronic blood loss and decrease of 
dietary intake can mediate absolute ID, but since HF is 
a chronic condition that promotes inflammatory status 
of the organism, functional ID due to cytokines and 
hepcidin overexpression can be present (Wong et al. 
2016).
To asset iron status, in human medicine, ferritin can 
be used. Indeed, ferritin has an important role in the 
inflammatory cycle and represents both a well-known 
marker of iron stores as well as an important biomarker 
of inflammation, that could be present in chronic dis-
eases (Bohn 2015). It has been reported that ferritin 
levels can be high in the presence of several pathologies 
such as acute respiratory distress syndrome, coronary 
artery disease, hypertension and myocardial infarction 
(Kell et al. 2014). 
Moreover, immunoassays for human serum ferritin 
cannot be used in other species, so individual assays still 
must be developed and calibrated for each species. 
(Andrews 2010) 
Chronic kidney disease (CKD) is a well-known 
comorbidity of HF and the presence of both conditions 
is known as Cardiorenal Syndrome, or Cardiovascular- 
-renal disorder (Pouchelon et al. 2015). Anaemia can 
be associated with both HF and CKD in human 
patients, which is commonly referred to as Cardiore-
nal-anaemia syndrome (Martinelli et al. 2016). 
The most common acquired heart disease affecting 
dogs and leading to HF is Myxomatous Mitral Valve 
Disease (MMVD), also known as endocardiosis, that 
can reach a prevalence close to 100% in elderly small 
breed dogs (Borgarelli et al. 2012).
To the best of our knowledge, no studies have 
examined iron status in dogs affected by MMVD, with 
or without CKD. Therefore, the aims of this study were 
to determine the iron status in dogs affected by MMVD, 
to analyse whether any differences in serum iron values 
were present between the American College of Veteri-
nary Internal Medicine (ACVIM) classes, between 
symptomatic and non-symptomatic patients for HF and 
with respect to selected echocardiographic parameters. 
Moreover, we investigated the possible existence of any 
difference in SIC among patients presenting MMVD 
and azotemia as a model of cardiovascular renal disor-
der.
A final aim was to evaluate the presence of an asso-
ciation between SID and patient’s survival time. 
Materials and Methods
This is a retrospective study performed on medical 
records and stored serum samples collected between 
January 2015 and June 2016 from dogs admitted to the 
Cardiology Unit of the Department of Veterinary Medi- 
cine (DIMEVET) of the University of Milan. 
The inclusion criteria were as follows: a diagnosis 
of MMVD and a complete medical record including 
physical examination, chest X-ray and echocardio-
graphic evaluation, complete blood count (CBC) and 
serum biochemical panel. All dogs affected by congeni-
tal or acquired heart diseases different from MMVD, 
as well as by systemic diseases, except chronic kidney 
disease (CKD), were excluded. 
A full echocardiographic examination was per-
formed using standardized thoracic imaging planes 
according to the recommendations of the American 
Society of Echocardiography (Thomas et al. 1993, 
Bonagura et al. 2000). From 2D view we obtained: 
Aortic root (Ao) and Left atrial (LA) dimension (right 
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parasternal short-axis view). Mitral valve inflow 
(E peak velocity, E/A ratio) and peak velocity of mitral 
and tricuspid regurgitations (MR and TR) were 
obtained through colour and spectral Doppler. We 
then calculated: left atrial-to-aortic root ratio (LA/Ao), 
End systolic volume index (ESVI), End diastolic 
volume index (EDVI), according to the Teichholz for-
mula normalized to body surface area (BSA). 
The MMVD patients were categorized based 
on the ACVIM classification (Atkins et al. 2009). 
As recommended by the ACVIM guidelines, stage B 
included dogs affected by MMVD without signs of 
CHF (namely, in stage B1, dogs without evidence 
of cardiac enlargement; in B2, dogs with signs of cardiac 
remodelling as LA and/or LV enlargement); stage C 
dogs with clinical signs of CHF due to MMVD, and 
stage D subjects presenting both clinical signs of CHF 
and refractoriness to standard medical treatments. 
(Atkins et al. 2009, Boswood et al. 2016). 
Doppler blood pressure (BP) measurements were 
performed in all patients as reported in the ACVIM 
guidelines, and was considered normal when ≤ 150 
mmHg (Brown et al. 2007).
The International Renal Interest Society (IRIS) 
guidelines were used to classify patients affected by 
CKD, and dogs were considered azotemic if their se-
rum creatinine (sCr) values were ≥ 1.4 mg/dl. Accor- 
ding to IRIS, patients were classified as IRIS 2 (sCr 
between 1.4 and 2 mg/dl), IRIS 3 (sCr between 2.1 and 
5.0 mg/dl) and IRIS 4 (sCr >5.0 mg/dl). Sub staging was 
performed based on BP and the presence of protein-
uria. Proteinuria was investigated trough urine creati-
nine to protein ratio (UPC) and considered present 
when UPC ≥ 0.5 (IRIS 2015).
Blood samples were collected from the brachioce-
phalic vein during routine clinical evaluation. For CBC, 
EDTA was used as anticoagulant, whereas for bio-
chemical evaluation, the blood was placed in tubes 
without anticoagulant and centrifuged at 3250 x g for 5 
minutes. The CBC was performed using an automated 
laser haematology analyser (Sysmex XT-2000iV; Sys-
mex corporation; Japan). For every CBC, red blood 
cells (RBC), haematocrit (Ht), haemoglobin (Hb), 
mean corpuscular volume (MCV), mean corpuscular 
haemoglobin concentration (MCHC), red distribution 
width (RDW) and platelet count were considered. 
Simultaneous evaluation of the blood smear was per-
formed and the degree of anisocytosis and poikilocyto-
sis was reported, together with a description of the 
main erythrocytes’ alterations. Anaemia was defined as 
a haematocrit value ≤ 37% (Tvedten et al. 2010). 
Routine biochemistry was carried out with an auto-
mated chemistry analyser (Cobas Mira; Roche diagnos-
tics, Switzerland) with reagents provided by Hagen 
diagnostic system (Italy). The serum samples were kept 
frozen (-20° C) until the iron analyses were performed. 
As described by Zaldivar-Lopez et al (2014), iron 
status was evaluated by measuring SIC (normal value 
90 - 200 mcg/dL) and total iron-binding capacity (TIBC, 
normal value 270-496 μg/dL); the TIBC was calculated 
by adding the unsaturated iron binding capacity (UIBC) 
to the SI. Percentage transferrin saturation (%SAT, 
normal value > 23%) was obtained using the formula 
%SAT = SI/TIBC x 100 (Andrews et al. 2010). 
Statistical analysis was performed using IBM SPSS 
Statistics 23 [Release 23.0.0.0]. Normality of the distri-
bution was tested using the nonparametric Shapiro 
Wilk test. Baseline descriptive statistics were presented 
as the mean and standard deviation for normally 
distributed continuous variables, whereas non-normally 
distributed variables were presented as median and 
interquartile (IQ) range. 
Differences in SIC, UIBC, TIBC and %SAT among 
ACVIM classes, between symptomatic and non-symp-
tomatic patients, between IRIS classes and between 
azotemic and non-azotemic patients were analysed by 
using One-Way ANOVA tests (normal distribution). 
Moreover, One-Way ANOVA tests (normal distribu-
tion) was used to determine the presence of statistical 
significant differences among ACVIM classes, between 
symptomatic and non-symptomatic patients, between 
IRIS classes and between azotemic and non-azotemic 
for selected echocardiographic parameters. 
The possibility for SID (dichotomous variable) to 
be a risk factor for dogs to be classified in a higher 
ACVIM classes was evaluated using an ordinal logistic 
regression by GLMs (Type I SS). The same model was 
performed for IRIS classes, whereas to evaluate SID 
when associated to azotemia, a binary logistic regres-
sion model was performed. The models were adjusted 
for age (continuous, computed in years), sex and size, 
which was considered as a dichotomous variable (small 
dogs ≤ 10 kg or medium > 10 kg). 
To verify the association between low SIC and 
selected echocardiographic parameters, other GLMs 
Type I were run. Each echocardiographic parameter 
was inserted in a model (linear distribution) and SID 
used as predictive variable. Models were adjusted for 
age, gender and size.
Survival was calculated as days between diagnosis 
and death (all causes of mortality) or between diagnosis 
and last contact with the owners (control visit or phone 
call). Subjects lost to follow-up were included in the 
survival analysis up until the last time at which they 
were known to be alive and then were thereafter cen-
sored in the analysis. The Kaplan-Meier method was 
used to estimate the survival function and plot time to 
event curves in the different groups; the equality of 
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survival distributions was tested using the Log-Rank 
method, and then univariate and multivariate Cox pro-
portional hazard analysis were used to evaluate the in-
fluence of different variables on survival. The variables 
considered were: presence/absence of clinical signs of 
CHF (dichotomous variable), age, sex, body weight, 
ACVIM class, RBC, Hb, Ht, RDW, SIC, low SIC 
(dichotomous variable), sCr, IRIS class, ESVI, EDVI, 
MR peak velocity, TR peak velocity, presence/absence 
of pulmonary hypertension (dichotomous variable), 
normalized left ventricular end diastolic and sistolic 
diameter calculated according to Cornell’s method 
of allometric scaling, La/Ao, E/A, peak velocity 
of E wave. 
P<0.05 was set to indicate statistical significance. 
Results
Two hundred seventy-six privately owned dogs were 
admitted to the Cardiology Service of the Department 
of Veterinary Medicine (DIMEVET) of the University 
of Milan between January 2015 and April 2016; among 
these, 116 (42%) were diagnosed with MMVD. Fifty- 
-four of these (46%) fulfilled the inclusion criteria and 
were thus enrolled in the study. 
The mean age of the dogs was 11 years (±3.2 SD), 
and median body weight was 11 kg (IQR 6 – 22). Most 
of the patients included were intact males (n=23, 43%), 
followed by neutered females (n=17, 31%), neutered 
males (n=8, 15%) and intact females (n=6, 11%). The 
most represented breeds were mongrels (n=24, 44%), 
Dachshund (n=4, 7%) and Cavalier King Charles 
(n=3, 6%). Breeds with less than three dogs were 
grouped and listed as “others” (n=21, 39%). Twenty- 
two dogs were classified as ACVIM B1 (41%), 14 as 
ACVIM B2 (26%), 15 as ACVIM C (28%) and 3 as 
ACVIM D (5%). Sixtyseven % (n=36) of the dogs were 
asymptomatic for CHF (ACVIM classes B1 and B2), 
and 33% were symptomatic (ACVIM classes C and D) 
(n=18). Most of the dogs were classified as IRIS class 1 
(80%, 44/54), 7 as class 2 (14%) and only 3 as IRIS class 
3 (6%). 
No dogs were classified as IRIS class 4. Non-azo-
temic dogs represented the 80% of the population 
(n=44), whereas 20% presented azotemia (n=10). 
The mean values of SIC, TIBC, UIBC and %SAT for 
different ACVIM classes and in symptomatic or 
non-symptomatic patients for CHF are reported in 
Table 1. The mean values of SIC, TIBC, UIBC and 
%SAT for different IRIS classes are reported in Table 2. 
The mean values of SIC, TIBC, UIBC and %SAT for 
Table 1. Mean (± SD) values of serum iron concentration (SIC), total iron binding capacity (TIBC), unsaturated iron binding capacity 
(UIBC) and percentage of saturation (%SAT) for different ACVIM classes and symptomatic vs. non-symptomatic patients for CHF. 
Non-symptomatic Symptomatic
ALL ACVIM B1 ACVIM B2 ACVIM C ACVIM D
SIC (μg/dL): 135.7 ± 49.84
140.86 ± 49.71 123.83 ± 53.38
144.18 ± 44.63 135.64 ± 58.21 134.53 ± 51.18 135.19 ± 51.11
TIBC (μg/dL): 423.06 ± 88.70
436.64 ± 74.79 395 ± 110.521
430.15 ± 71.12 446 ± 83.23 384.25 ± 125.56 427 ± 88.7
UIBC (μg/dL): 287.36 ± 78.55
261.22 ± 215.53 284.94 ± 252.79
207.75 ± 243.64 350.33 ± 120.49 270.6 ± 274.76 356.67 ± 73.87
%SAT: 32.33 ± 10.39
31.8 ± 10.65 26.562 ± 10.04
32.71 ± 10.7 30.67 ± 10.95 28.97 ± 9.28 16.92 ± 7.63
Table 2. Mean (± SD) values of serum iron concentration (SIC), total iron binding capacity (TIBC), unsaturated iron binding 
capacity (UIBC) and percentage of saturation (%SAT) for different IRIS classes. 
IRIS 1 IRIS 2 IRIS 3
SIC (μg/dL) 141.26 ± 53.87 111.43 ± 29.9 105.33 ± 38.28
TIBC (μg/dL) 426 ± 80.29 416.83 ± 142.93 406.5 ± 19.09
UIBC (μg/dL) 265.92 ±245.7 332.43 ± 121.4 165.67 ± 211.47
%SAT 30.69 ± 11.71 26.34 ± 4.96 30.02 ± 10.80
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azotemic and non-azotemic dogs are reported in 
Table 3.
The prevalence of SID in our population of 
dogs with MMVD was 18% (10/54). Among the dogs 
non-symptomatic for CHF (ACVIM B1 and B2), 11% 
presented SID (n=4), whereas in the symptomatic 
group for CHF (ACVIM C and D), the prevalence of 
SID was 33% (n=6). All the dogs classified as ACVIM 
D (3/3, 100%) presented low SIC. 
Eight out of ten dogs (80%) with SID were classi-
fied as IRIS class 1. 
TIBC was within or above the reference range in 
6/10 of SID dogs (60%), and %SAT was below the mini- 
mum level in 4/10 of them (40%). 
No significant differences in the SIC, UIBC, TIBC 
and %SAT values between the ACVIM classes or IRIS 
classes nor between the symptomatic and non-symp-
tomatic patients were found, nor any differences ac-
cording to drugs administered to the patients, basically 
diuretics, ACE inhibitors or inodilator, aimed to con-
trol HF. Between the azotemic and non-azotemic pa-
tients the difference in mean SIC values was statistical-
ly significant (p-value=0.02); on the contrary, no 
significant differences in UIBC, TIBC and %SAT were 
observed. 
Only 1 patient (2%) presented low SIC and concur-
rent anaemia. The prevalence of anaemia in the whole 
MMVD population was 6% (3/54). Analysis of the 
blood smear revealed no substantial alterations in 
dimension or morphology of the erythrocytes, except 
microcytosis in 2/10 (20%) dogs with low SIC. The only 
patient presenting a mild degree of poikilocytosis with 
presence of codocytes and schistocytes was the dog with 
low SIC and concurrent anaemia. MCV was below the 
reference interval in 1/54 dogs (2%), with concurrent 
microcytosis highlighted at the blood smear analysis. 
MCHC was in the reference range for all the dogs 
included. RDW was above the reference interval for 
3/54 dogs (5%), one of them presenting low SIC and 
concurrent anaemia. 
Biochemical analysis was unremarkable for all the 
dogs included in the study, except for the dogs included 
as azotemic, that all presented elevated sCr. Only 1 dog 
over 10 presenting low SIC (10%) had concurrent 
hypoproteinaemia, known condition that can affect SIC 
(Bohn et al. 2015). 
Statistical analysis by GLM revealed that dogs with 
SID were at higher risk of being included in a higher 
ACVIM class when compared with dogs with normal 
levels of iron (OR=6.383, p-value=0.014). The data 
were adjusted for age, sex and body size (Table 4). 
In contrast, SID (adjusted for age, sex and size) was 
neither associated with an increase in IRIS classes nor 
considered a risk factor for azotemia.
Mean values for different echocardiographic para- 
meters of the dogs included in the study are presented 
in Table 5. ANOVA revealed that statistical significant 
differences were present between different ACVIM 
Table 3. Mean (± SD) values of serum iron concentration (SIC), total iron binding capacity (TIBC), unsaturated iron binding 
capacity (UIBC) and percentage of saturation (%SAT) for azotemic and non-azotemic dogs.
Non-azotemic Azotemic
SIC (μg/dL) 141.26 ± 53.87* 111.45 ± 29.58*
TIBC (μg/dL) 426 ± 80.29 415.22 ± 113.32
UIBC (μg/dL) 265.92 ± 245.696 283.36 ± 153.74
%SAT 30.68 ± 11.71 27.51 ± 5.74
* p-value = 0.02 (One-Way ANOVA, Brown and Forsythe Test)
Table 4. Evaluation of SID as a risk factor for a worst ACVIM classification in dogs through a GLM (Type I SS) ordinal logistic 
regression (adjusted for age, body size and sex).
Variable Category OR (95% CI) P-value
SID
O (= No deficiency; reference) 1
1 (= deficiency) 6.38 (1.46-27.94) 0.014
Age (continuous) 1.25 (1.02-1.53) 0.032
Body size
(dichotomous)
Medium (> 10 kg) (reference) 1




Males 3.82 (1.13-12.95) 0.031
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classes and between symptomatic and non-symptoma- 
tic patients for: EDVI (ml/m2), La/Ao ratio, E/A and 
TR peak velocity. No statistically significant differences 
were found in echocardiographic parameters between 
IRIS classes and between azotemic and non azotemic 
patients. 
Statistical analysis by GLMs revealed that dogs with 
SID were at higher risk of have certain echocardio-
graphic parameters altered, including a higher La/Ao 
ratio (OR=1.50, p=0.018) and TR peak velocity 
(OR=1.88, p=0.023), and a lower MR peak velocity 
(OR=0.49, p=0.002).
Log-rank analysis showed shorter survival in 
MMVD dogs with SID (p-value=0.020). The median 
survival times (MST) were 201 days for dogs presenting 
low SIC and 296 days for dogs with normal SIC. Uni-
variate Cox analysis showed statistical significant re-
sults in determining survival for some of the considered 
variables. Hazard ratios are reported in Table 6. Multi-
variate Cox analysis revealed that only age and the 
presence of CHF symptoms could affect the dogs’ sur-
vival (Table 7). 
Discussion 
In our population, dogs diagnosed with MMVD 
and presenting low SIC had a prevalence of 18%. 
The prevalence of SID among dogs presented with 
HF due to MMVD (ACVIM C and D) was 33%. 
The 100% of the dogs admitted with acute decompen-
sated CHF presented SID.
Table 5. Mean (± SD) values in selected echocardiographic parameters for different ACVIM classes
Echocardiographic parameter Class Class Class P value
ACVIM B1 ACVIM B2 ACVIM C
ESVI(ml/m2): 28.06 ± 8.90 26.50 ± 12.03 27.23 ± 15.97
EDVI(ml/m2): 88.81 ± 30.72* 124.47 ± 27.91 153.21 ± 30.24* 0.00
La/Ao ratio: 1.18 ± 0.19* 1.95 ± 0.45 2.23 ± 0.40* 0.00
E/A: 1.13 ± 10.7* 1.2 ± 0.45 1.66 ± 0.72* 0.01
MR V max: 5.63 ± 0.51 5.45 ± 0.56 5.88 ± 0.78
TR V max: 1.96 ± 0.48* 2.77 ± 0.62 2.78 ± 0.69* 0.03
* One-Way ANOVA, Brown and Forsythe Test
Table 6. Single hazard ratios (HRs) presented in Cox proportional-hazards survival univariate analysis.
Variable HR (95% CI) P-value
Age (continuous) 1.406 (1.11-1.78) 0,004
Body weight (continuous) 0.92 (0.85-0.99) 0.023
RDW 1.22 (1.02-1.45) 0.027
EDVI(ml/m2): 1.021 (1.00-1.03) 0.000
La/Ao ratio: 4.77 (1.8-12.63) 0.002
E wave peak velocity: 5.01 (1.32-19.02) 0.018
Pulmonary Hypertension (dichotomous) 3.216 (1.16-8.90) 0.025
Clinical symptoms of CHF (dichotomous) 13.827 (3.10-61.61) 0.001
Ejection fraction (EF) 1.12 (1.05-1.2) 0.001
sCr 3.03 (1.22-7.51) 0.016
Table 7. Single hazard ratios (HRs) presented in Cox proportional-hazards survival multivariate analysis.
Variable HR (95% CI) P-value
Age (continuous) 1.7 (1.15-2.5) 0,008
Clinical symptoms of CHF (dichotomous) 8.31 (1.64-42.09) 0.011
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No significant differences in mean SIC between 
ACVIM classes and between symptomatic and 
non-symptomatic patients were found, although the 
60% of dogs with low SIC were symptomatic for HF. 
Moreover, based on GLM analysis, dogs presenting 
with low SIC have a 6.3-times higher risk to be included 
in a higher ACVIM class when compared with dogs 
presenting normal SIC. 
Low SIC should then be considered a risk factor for 
disease progression, together with age, sex and size, 
that reached statistical significance. 
Old, male, small size breed dogs with low SIC are at 
higher risk of being included in a higher ACVIM class.
It is true that the prevalence of low SIC in affected 
dogs is lower than the percentage reported for human 
patients affected by HF, where the value stands at ap-
proximately 50% (Klip et al. 2013, Fitzsimmons et al. 
2015), but most of the studies on humans are performed 
on hospitalized patients, who present more severe con-
ditions than those found in our canine population, in 
which only 3 subjects belonged to ACVIM class D. 
Nevertheless, the 33% of dogs classified as symptomat-
ic for HF, had low SIC. If we then compare the preva-
lence of SID between symptomatic canine patients and 
the human population affected by HF, the percentages 
are quite smilar. 
The pathogenetic hypotheses proposed to explain 
ID in HF are, among others, insufficient dietary iron 
intake, poor gastrointestinal iron absorption due to 
intestinal mucosa oedema and hepcidin overexpression 
related to chronic inflammatory state in HF (Van der 
Meer et al. 2004, Opasich et al. 2005, Kazory et al. 2009). 
In veterinary medicine, anorexia, like it is seen at 
late stage of HF, is a quite concerning topic for owners 
and a study from Mallery et al. (1999) reported that is 
one of the most common reasons for owners to choose 
euthanasia during late-stage HF (Mallery et al. 1999). 
Anorexia leading to low SIC is not something common 
in veterinary medicine. Moreover, dogs are normally 
fed balanced diets, which help to prevent any kind of 
dietary insufficiency. Dogs’ diets are usually rich in 
meat products, making dietary haeme, an important 
iron source released from dietary myoglobin and 
haemoglobin, more bioavailable. (Harvey 2008) 
Even the iron metabolism is different between hu-
mans and dogs. Normally, ferric iron ions (Fe+3) de-
rived from diet are reduced to ferrous iron ions (Fe+2) 
so that they can be absorbed by duodenal enterocytes. 
(Harvey 2008) This is certainly necessary for humans 
but not fundamental for dogs, where the absorption 
of the two valence forms is equal (Moore et al. 1944, 
Harvey 2008). 
Oedema of the GI tract and hepatic stasis are com-
mon in HF and can be associated with poor iron ab-
sorption from dietary sources. The different pathway of 
absorption between dogs and humans could offer a par-
tial explanation why dogs affected by HF could have 
less problems related to iron absorption. 
On the other hand, anorexia in symptomatic CHF, 
in conjunction with GI oedema and the inflammatory 
status that is related to the presence of CHF could offer 
a possible explanation for SID in dogs symptomatic for 
HF, where is more prevalent. 
It is known that HF is a chronic condition that pro-
motes inflammatory status of the organism, and this 
can alter iron metabolism inducing functional ID, due 
to cytokines and hepcidin overexpression. TIBC and 
%SAT values were used to this purpose, and the results 
seem to suggest that, in our dogs, ID is more frequently 
absolute (primary) than functional (secondary to 
inflammatory conditions). In fact, in real iron deficien-
cy, TIBC is usually normal or slightly over the reference 
interval, and %SAT is lower, in functional iron defi-
ciency both TIBC and %SAT are lower than the refer-
ence intervals (Harvey 2008, Andrews 2010). 
It is stated that, in human medicine, ID can be pre- 
sent in the absence of anaemia and is associated with 
the worst symptoms. With respect to anaemia, only one 
patient in our sample presented anaemia and SID; 
therefore, SID can effectively be present without anae-
mia in dogs with HF, as reported in literature regarding 
human patients (Okonko et al. 2011, Klip et al. 2013, 
Arora et al. 2014, Rangel et al. 2014, Fitzsimmons et al. 
2015). In fact, anaemia is commonly considered 
a late-onset condition that can be preceded by ID 
(Harvey 2008). 
Although a statistically significant difference was 
found in the median iron values between azotemic and 
non-azotemic patients, it is important to highlight that 
the 80% of dogs that presented SID were classified as 
IRIS class 1; SID does not appear to be an exclusive 
finding of renal complication of cardiovascular disease 
(cardiorenal syndrome), and we should consider it as 
possible comorbidity in HF alone (Rangel et al. 2014, 
Fitzsimmons et al. 2015). 
Regarding survival, MST, calculated trough Kaplan- 
-Meier, were significantly different in dogs with or with-
out SID. Univariate Cox regression revealed the impact 
of changes in echocardiographic variables related to 
severity of MMVD in shortening survival, in particular 
increase in EDVI, La/Ao ratio, ejection fraction and E 
wave peak velocity and presence of pulmonary hyper-
tension. Moreover, increase in age and in sCr were as-
sociated with shorter survival. Finally, presence of clini- 
cal symptoms of CHF decrease survival times. SIC was 
not associated with shorter survival, but RDW was, sug-
gesting that alteration in RBC dimensions, that can be 
mediated by low SIC, and consequent reduced oxygen 
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transport can alter energetic metabolism and heart 
work and shorten patients’ survival. Still, in a multi- 
variate Cox analysis, only increase in age and the pres-
ence of clinical symptoms are related to shorter survi- 
val. It is important to remind that survival results should 
be interpreted with caution due to the small number of 
dogs included in the study and the small percentage 
of dogs that experienced death in our sample. 
With respect to therapeutic options, oral supple-
mentation with ferrous sulphate is the safest and least 
expensive way of treating SID in dog (Plumb 2008, 
Kerl et al. 2014), but its intestinal absorption is limited 
in healthy animals, and even more in HF due to intesti-
nal mucosal oedema. However, no specific side effects 
are reported for iron oral therapies. Therefore, the 
authors speculate that investigation of iron status in 
dogs affected by MMVD in order to introduce an iron 
supplementation if needed seems legitimate.
Intravenous (IV) iron therapy showed promising 
results in human patients affected by HF in improving 
exercise capacity, left ventricle function and quality 
of life (Gutzwiller et al. 2013, Toblli et al. 2015). No 
studies are reported in veterinary medicine about this. 
There are several limitations in our study. We are 
aware that the measurement of serum iron represents a 
small fraction of the total body iron and therefore we 
decided to also measure transferrin (TIBC) and per-
centage of saturation. Indeed, the main limitation can 
be found in the impossibility, at the moment, to mea-
sure ferritin and hepcidin, which are fundamental in 
the diagnostic algorithm and can be useful markers to 
characterize SID. Ferritin in particular is considered 
one of the diagnostic cornerstones of all the study about 
iron deficiency in cardiovascular diseases in human 
medicine. Moreover, limitations have to be searched 
in  the retrospective nature of the study. Finally, the limi- 
ted sample numbers, in particular for the most severe 
ACVIM class (D), make it harder to draw conclusions 
for this class of patients. Strict inclusion criteria were 
applied to improve reliability, that decreased sample 
size. Small sample size and underrepresentation of 
ACVIM class C and D could have biased some of the 
results.
In conclusion, SID is a relatively frequent condition 
associated to MMVD in dogs; it is present in almost 
20% of patients affected by MMVD, but the percent-
age raise to the 33% in symptomatic patients and to 
100% in patients presenting acute decompensated 
CHF.
SID represents a risk factor for dogs affected by 
MMVD: low SIC is associated with a 6.3-times higher 
risk of being included in a higher ACVIM class. More-
over, dogs presenting low SIC have a 1.5 times higher 
risk of presenting an increase in La/Ao ratio. 
The 14% of ACVIM B2 dogs presented low SIC: 
in the authors opinion, monitoring the iron status in 
dogs with preclinical MMVD over time could provide 
information about SID as a comorbidity in HF and, 
maybe, also about the trend of the pathology.
Oral supplementation of iron could be an effective 
and safe way to restore iron levels in these dogs, 
although its efficacy could be affected by lack of intesti-
nal absorption. Further studies are needed in a larger 
population with evaluation of iron storage (i.e., ferritin 
levels, hepcidin) as well as the feasibility of IV iron sup-
plementation, especially in acute decompensated CHF.
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